Id4基因启动子甲基化在髓系白血病完全缓解期监测中的意义  

Significance of Id4 Promoter Methylation in Monitoring AML Patients with Completely Remission

作　　者：赵瑜[1] 王全顺[1] 李红华[1] 薄剑[1] 窦丽萍[1] 靖彧[1] 王书红[1] 于力[1] 

机构地区：[1]中国人民解放军总医院血液科,北京100853

出　　处：《中国实验血液学杂志》2008年第3期476-478,共3页Journal of Experimental Hematology

基　　金：国家自然科学基金资助项目;编号39970318;973国家重点基础研究专项经费资助项目;编号2005CB522400

摘　　要：本研究探讨id4基因甲基化在完全缓解急性髓系白血病(AML)病情监测中的意义。采用甲基化特异性PCR(MS-PCR)对经诱导缓解和巩固强化4-5疗程后持续完全缓解的AML患者进行id4基因启动子区甲基化状况分析,并随访。结果表明:id4基因在32例AML中有15例id4基因甲基化,其中7例在随访期间出现复发或复发倾向。17例id4基因非甲基化的患者在随访期间完全缓解。结论:在完全缓解的AML患者中进行id4基因启动子区甲基化检测可在一定程度上预测白血病的复发。The study was purposed to investigate the significance of id4 gene promoter methylation in monitoring AML patients with complete remission （CR）. Methylation specific-PCR （MS-PCR） were used to detect the status of promoter methylation of id4 gene in bone marrow samples from AML patients with CR who had accepted induction with DA or IA and 4 to 5 consolidation chemotherapy with Ara-C. The results showed that in the all 32 patients, 15 were found to show id4 promoter methylation and 7 out of the 15 were found relapsed or tendency to relapse in the following- up period. While all the 17 patients with id4 unmethylation were still in their CR status in the same period. In conclusion, id4 promoter methylation might be a predictor for relapse of AML patients with CR in certain degree.

关 键 词：ID4基因 基因甲基化 髓系白血病 白血病复发 

分 类 号：R733.7[医药卫生—肿瘤]